摘要
目的评价阿加曲班应用对早期急性脑梗死患者溶栓的疗效影响,并在保障疗效基础上,提高患者的生存质量。方法选择医院2018年1月至2019年8月收治的急性脑梗死患者82例,在阿替普酶静脉溶栓治疗的基础上随机分组(试验1组、试验2组)。试验1组静脉滴注依达拉奉治疗,试验2组配合阿加曲班治疗。比较两组急性脑梗死患者细胞因子水平、神经功能缺损程度、日常生活能力状况以及临床疗效。结果试验2组患者治疗后细胞因子水平以及日常生活能力等指标评分改善情况均明显优于试验1组,且治疗后临床总有效率明显高于试验1组,经统计学计算P<0.05。结论阿加曲班对早期急性脑梗死患者溶栓后神经功能缺损、生活质量、细胞因子水平改善有积极的影响,且提高了预后效果。
Objective To evaluate the effect of agatraban on patients with early acute cerebral infarction after thrombolysis,and improve the quality of life of patients on the basis of improving the prognosis of patients with acute cerebral infarction.Methods A total of 82 patients with acute cerebral infarction who were treated in our hospital from January 2018 to August 2019 were randomly divided into two groups(trial group 1 and trial group 2)on the basis of intravenous thrombolysis with ateplase.The first group was treated with edaravone and the second group with agatraban.The level of cytokines,the degree of neurological deficit,the state of daily living ability and the clinical effect were compared between two groups.Results The improvement of cytokine level and daily life ability of the patients in the two groups was significantly better than that in the first group,and the total clinical effective rate was significantly higher than that in the first group(P<0.05).Conclusion Agatraban has a significant positive effect on the improvement of neurological deficit,quality of life and cytokine level in patients with early acute cerebral infarction after thrombolysis,and improves the prognosis of the treatment.
作者
王莹
WANG Ying(Department of Neurology,Fushun Central Hospital,Fushun 113006,China)
出处
《中国医药指南》
2022年第8期77-79,共3页
Guide of China Medicine
关键词
早期急性脑梗死
阿加曲班
溶栓治疗
细胞因子
Early acute cerebral infarction
Agatraban
Thrombolytic therapy
Cytokines
